Skip to main content
EJNMMI Research
Figure 3 | EJNMMI Research

Figure 3

From: FDG-PET is a good biomarker of both early response and acquired resistance in BRAFV600 mutant melanomas treated with vemurafenib and the MEK inhibitor GDC-0973

Figure 3

FDG-PET imaging. FDG-PET imaging is effective for monitoring vemurafenib and GDC-0973 combination drug action in BRAFV600E mutant and resistant xenografts. (A) A375- and (B) A375 R1-resistant KRAS mutant melanomas were implanted in athymic nude mice and were administered vehicle, vemurafenib (50 mg/kg BID) or vemurafenib (50 mg/kg BID) and GDC-0973 (7.5 mg/kg QD). Dynamic FDG-PET imaging was performed at baseline, day 3 and day 6 after treatment. A reduction in Ki and MRGlucMAX was induced on day 6 of imaging by both vemurafenib and 0973 combination treatment (Student's t test showing standard error of the mean A375: MRGlucMax − vemuraf; *p = 0.02, combination; **p = 0.01, Ki − vemuraf; *p = 0.02, combination; **p = 0.001, tumor volume; ***p = 0.001. A375R1: MRGlucMax − vemuraf; *p = 0.04, tumor volume; ***p = 0.001). White arrow points at the tumor.

Back to article page